在65岁以下男性中,伯明翰髋关节表面置换的生存率是否优于选定的常规全髋关节置换术?来自澳大利亚骨科协会国家关节置换登记处的研究
该研究基于澳大利亚骨科协会国家关节置换登记处(AOANJRR)数据,比较了65岁以下男性骨关节炎患者中伯明翰髋关节表面置换(BHR,股骨头≥50 mm)与三种10年累积翻修率最低的常规全髋关节置换(THA)的翻修情况。结果显示,BHR在17年时的全因翻修率显著高于所选常规THA(HR 2.77 [95%CI 1.78至4.32];p<0.001)。作者建议向患者告知这一风险,并认为对于关注假体耐久性的患者,低翻修率的THA可能是更好的选择。
要点
- 在目标人群中,BHR 17年全因翻修率显著高于三种最佳常规THA(HR 2.77;95%CI 1.78至4.32;p<0.001)。
- BHR因松动(2年后)和骨折的翻修率均显著高于常规THA,感染翻修率在5年内较低。
- 作者建议向患者告知BHR的翻修风险,并认为低翻修率THA可能是更好选择。
核心结论
- 鉴于BHR在目标人群中相比性能更好的常规THA假体翻修风险增加,作者推荐向患者告知这一风险。
- 作者建议,对于关注假体耐久性的患者,具有已验证低翻修率的THA可能是更好的选择。
- 作者认为,需要良好对照的前瞻性研究显示BHR在现代轴承常规THA面前具有可观的临床重要患者报告结局和功能结果优势,才能证明BHR的使用合理。
研究设计与样本
- 研究使用澳大利亚骨科协会国家关节置换登记处(AOANJRR)1999年9月1日至2018年12月31日报告的数据进行分析。
- 研究人群为因骨关节炎接受单侧髋关节置换的65岁以下男性,排除所有双侧手术患者。
- BHR组纳入股骨头尺寸≥50 mm的BHR假体,常规THA组纳入股骨头尺寸≥32 mm且为陶瓷对陶瓷或金属、陶瓷、陶瓷化金属对交联聚乙烯(XLPE)轴承的假体。
- BHR手术4790例,常规THA手术2696例;BHR组平均年龄52±7.8岁,常规THA组平均年龄56±7.1岁。
- 两组最大随访时间均为18.7年,BHR组平均随访11.9年,常规THA组平均随访9.3年;所有比较分析均对年龄进行了调整。
主要发现
- BHR组17年全因翻修率显著高于所选常规THA组(HR 2.77 [95%CI 1.78至4.32];p<0.001)。
- BHR组2年后因松动的翻修率高于常规THA组(HR 4.64 [95%CI 1.66至12.97];p=0.003)。
- BHR组整个研究期间骨折翻修率高于常规THA组(HR 2.57 [95%CI 1.24至5.33];p=0.01)。
- BHR组感染翻修率在最初5年低于常规THA组,此后两组无差异。
- BHR组所有翻修均为大翻修,占初次BHR手术的4.5%;常规THA组大翻修占1.7%,另有0.6%的小翻修。
临床怎么用
- 作者推荐向患者告知BHR相比性能更好的常规THA假体在目标人群中翻修风险增加。
- 作者建议,对于关注假体耐久性的患者,具有已验证低翻修率的THA可能是更好的选择。
- 作者认为,需要良好对照的前瞻性研究显示BHR在现代轴承常规THA面前具有可观的临床重要患者报告结局和功能结果优势,才能证明BHR的使用合理。
局限性
- ASA评分和BMI仅分别自2012年和2015年起纳入AOANJRR数据收集,因此后BHR在澳大利亚使用量低,未纳入本分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Birmingham Hip Resurfacing (BHR) prosthesis is the most commonly used metal-on-metal hip resurfacing arthroplasty device. The current manufacturer-recommended target demographic for the BHR is male patients, younger than 65 years requiring a femoral head size of ≥ 50 mm. Female patients, older patients, and individuals with smaller femoral-head diameter (≤ 50 mm) are known to have higher revision rates. Prior studies suggest that the survivorship of the BHR when used in the target demographic is comparable with that of primary conventional THA, but comparing survivorship of the most durable hip resurfacing arthroplasty device to the survivorship of all conventional THA prostheses is not ideal because the THA group comprises a large number of different types of prostheses that have considerable variation in prosthesis survival. A more informative comparison would be with the THA implants with the best survivorship, as this might help address the question of whether survivorship in the BHR target population can be improved by using a well-performing conventional THA. QUESTIONS/PURPOSES: We compared the difference in cumulative percent revision, reasons for revision and types of revision for procedures reported to the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) using the BHR prosthesis (femoral-head size > 50 mm) and three conventional THA prostheses identified as having the lowest 10-year cumulative percent revision in the currently recommended BHR target population to ask: (1) Does the BHR have a lower cumulative revision rate than the group of three conventional THA prostheses? (2) Is there a difference in the revision diagnosis between the BHR and the three best conventional THA prostheses? (3) What is the difference in the components used for a revision of a BHR compared with the three best conventional THA prostheses? METHODS: Data reported to the AOANJRR between September 1, 1999 and December 31, 2018 was used for this analysis. This study period includes almost the entire use of the BHR in Australia. The AOANJRR is a large national joint registry with almost 100% completeness, high accuracy, rigorous validation, and little to no loss to follow-up. The study population included males younger than 65 years that had received one hip replacement procedure for osteoarthritis. All patients with bilateral procedures, no matter the time interval between hips, were excluded. Only BHR prostheses with a femoral-head size ≥ 50 mm and conventional THA prostheses with femoral head sizes ≥ 32 mm and either ceramic-on-ceramic or metal, ceramic, ceramicized metal-on-crosslinked polyethylene (XLPE) bearings were included. These femoral head sizes and bearings were selected because they reflect modern conventional THA practice. There is no difference in the revision rate of these bearings in the AOANJRR. There were 4790 BHR procedures and 2696 conventional THA procedures in the study group. The mean (± SD) age for BHR procedures was 52 ± 7.8 years and 56 ± 7.1 years for conventional THA procedures. All comparative analyses were adjusted for age. Other demographics data including American Society Anesthesiologists (ASA) score and BMI were only included in AOANJRR data collection since 2012 and 2015, respectively, and have not been included in this analysis because of the low use of BHR in Australia since that time. The maximum follow-up was 18.7 years for both groups and mean follow-up of 11.9 years for the BHR and 9.3 years for the conventional THA group. Revision rates were determined using Kaplan-Meier estimates of survivorship to describe the time to the first revision, with censoring at the time of death or closure of the database at the time of analysis. A revision was defined as removal, replacement or addition of any component of a joint replacement. Revisions can be further classified as major revisions (removal of a component articulating with bone-usually the stem and/or the shell) or minor revisions (removal of other components-usually the head and/or the liner). The unadjusted cumulative percent revision after the primary arthroplasty (with 95% confidence intervals) was calculated and compared using Cox proportional hazard models adjusted for age. RESULTS: The BHR prosthesis had a statistically higher rate of all-cause revision at 17 years than the selected conventional THA prostheses (HR 2.77 [95% CI 1.78 to 4.32]; p < 0.001). The revision diagnoses differed between the groups, with the BHR demonstrating a higher revision rate for loosening after 2 years than the conventional THA protheses (HR 4.64 [95% CI 1.66 to 12.97]; p = 0.003), as well as a higher fracture rate during the entire period (HR 2.57 [95% CI 1.24 to 5.33]; p = 0.01). There was a lower revision rate for infection for the BHR compared with the THA group in the first 5 years, with no difference between the two groups after this time. All revisions of the BHR were major revisions (such as, removal or exchange of the femoral and/or acetabular components) and this occurred in 4.5% of the primary BHR procedures. Major revision was the most common type of revision for primary THA accounting for 1.7% of all primary THA procedures. Minor revisions (head, inset or both) were undertaken in a further 0.6% of primary THA procedures. CONCLUSIONS: Given the increasing revision risk of the BHR compared with better-performing conventional THA prostheses in the target population, we recommend that patients be counseled about this risk. We suggest that a THA with proven low revision rates might be the better choice, particularly for patients who are concerned about implant durability. Well-controlled prospective studies that show appreciable clinically important differences in patient-reported outcomes and functional results favoring the BHR over conventional THA prostheses using modern bearings are needed to justify the use of the BHR in view of this revision risk. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Stoney J, Graves SE, de Steiger RN, et al. Is the Survivorship of Birmingham Hip Resurfacing Better Than Selected Conventional Hip Arthroplasties in Men Younger Than 65 Years of Age? A Study from the Australian Orthopaedic Association National Joint Replacement Registry. Clin Orthop Relat Res. 2020. PMID: 32898048. doi:10.1097/CORR.0000000000001453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。